Skip to main content

Table 1 Patient Characteristics

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Variables

Startification

Over all

BDca

GBca

Spieces of cancer

 

42

27

15

Sex

(male/female)

(24/18)

(17/10)

(7/8)

Age

 

66.5 ± 7.5

64.8 ± 8.2

69.5 ± 4.7

ECOG PS

(0/1/2)

(36/4/2)

(22/4/1)

(14/0/1)

Disease Status

(unresectable/postoperative recurrence)

(26/16)

(15/12)

(11/4)

Disease extension

locally advanced (primary)

26

15

11

 

local recurrence

7

7

0

 

liver metastasis

9

4

5

 

lung metastasis

4

3

1

 

lymphnode metastasis

11

4

7

 

miscellaneous metastasis

5

5

0

Tumor marker

carcinoembryonic antigen (CEA)

16.7 ± 60.7

6.4 ± 17.2

36.7 ± 100.5

 

CA19-9

3035.5 ± 9507.6

4495.3 ± 11688.8

407.9 ± 587.2

Previous chemotherapy

(yes/no)

(4/38)

(3/24)

(1/14)

  1. Abbreveations
  2. BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status